Instil Bio (TIL)
Nasdaq Market Closed
Instil Bio, Inc. is a clinical-stage biotechnology company developing cell therapies for cancer. The company’s work centres on tumor infiltrating lymphocytes, or TILs, which are immune cells found within a patient’s tumour that can be expanded and enhanced outside the body before being returned as a potential treatment. Instil Bio trades on Nasdaq under the symbol TIL.
The company’s approach is part of the broader field of adoptive cell therapy, where a patient’s own immune cells are used to target cancer. Traditional autologous TIL therapy involves collecting tumour tissue, identifying and growing T cells that recognise cancer cells, and reinfusing those cells after preparative treatment. Instil Bio has also worked on next-generation engineered TIL programmes intended to improve potency, tumour recognition and persistence in difficult-to-treat solid tumours.
A key element of its platform is CoStAR, short for Co-Stimulatory Antigen Receptor. This technology is designed to engineer TILs with additional signalling capability when they encounter selected tumour-associated antigens. The company’s pipeline has included ITIL-306, a programme designed to recognise an antigen expressed in several solid tumour types, including ovarian, uterine, non-small cell lung and renal cancers.
As a development-stage biopharmaceutical company, Instil Bio does not resemble a diversified pharmaceutical manufacturer. Its value is tied to clinical progress, safety and efficacy data, regulatory interactions, manufacturing execution and access to capital. The company operates in a high-risk, high-potential area of oncology research, where scientific differentiation and clinical validation are central to long-term prospects.
Last updated
- Market Cap
- 55M
- P/E
- —
- P/FCF
- —
- P/S
- 24.53
- Enterprise Value
- 134.98M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 3963 MAPLE AVENUE, DALLAS, TX, 75219
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of First Solar, Inc. - FSLR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AST SpaceMobile, Inc. - ASTS
Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
What Makes Instil Bio (TIL) a New Buy Stock
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why
Instil Bio Announces Strategic Update
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 55M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 134.98M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.5
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 24.53
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -2.33
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 60.2
- EPS
- -6.99
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -42.8%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -23.64%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.77
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 39.84
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 39.84
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.06
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 27.97K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 8.11
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | 2.24M | — | — |
| Gross profit | — | — | 2.24M | — | — |
| Operating income | -7.01M | -16.28M | -12.78M | -23.44M | -30.56M |
| EBITDA | -6.01M | -16.27M | -12.77M | -22.89M | -13.98M |
| Net income | -4.2M | -8.19M | -13.59M | -21.39M | -28.2M |
| Basic EPS | -0.62 | -1.17 | -2.01 | -3.24 | -4.32 |
| Diluted EPS | -0.62 | -1.17 | -2.01 | -3.24 | -4.32 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 200.43M | 203.52M | 211.77M | 230.99M | 237.45M |
| Total liabilities | 89.73M | 89.66M | 91.35M | 99.32M | 92.54M |
| Total equity | 110.7M | 113.87M | 120.42M | 131.67M | 144.91M |
| Cash & equivalents | 5.02M | 6.64M | 5.8M | 7.69M | 15.37M |
| Current assets | 188.18M | 191.26M | 195.98M | 207.24M | 218.3M |
| Current liabilities | 4.72M | 4.84M | 5.7M | 13.85M | 7.23M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -1.34M | -7.08M | -10.56M | -14.79M | -4.2M |
| Investing cash flow | -317K | 7.82M | 8.45M | -400K | 9.61M |
| Financing cash flow | — | 0 | 378K | 6.68M | 232K |
| Change in cash | -1.65M | 742K | -1.73M | -8.51M | 5.65M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | 10-Q — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — Instil Bio, Inc. | View Filing | |
| edgar index | DEFA14A — Instil Bio, Inc. | View Filing | |
| edgar index | ARS — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-8 — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | 10-K — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G/A — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | 10-Q — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Instil Bio, Inc. | View Filing | |
| edgar index | 144 — Instil Bio, Inc. | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | 10-Q — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Instil Bio, Inc. | View Filing | |
| edgar index | 4 — Instil Bio, Inc. | View Filing | |
| edgar index | 4 — Instil Bio, Inc. | View Filing | |
| edgar index | 4 — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — McGaughy R Kent Jr | View Filing | |
| form 4 | Form 4 — Matcham George | View Filing | |
| form 4 | Form 4 — Gibson Neil W | View Filing | |
| form 4 | Form 4 — Binder Gwendolyn | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Instil Bio, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | 10-Q — Instil Bio, Inc. | View Filing | |
| edgar index | DEFR14A — Instil Bio, Inc. | View Filing | |
| edgar index | 4 — Instil Bio, Inc. | View Filing | |
| edgar index | 4 — Instil Bio, Inc. | View Filing | |
| form 4 | Form 4 — Crouch Bronson | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| edgar index | DEF 14A — Instil Bio, Inc. | View Filing | |
| edgar index | DEFA14A — Instil Bio, Inc. | View Filing | |
| edgar index | ARS — Instil Bio, Inc. | View Filing | |
| edgar index | 424B5 — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | 10-K — Instil Bio, Inc. | View Filing | |
| edgar index | S-8 — Instil Bio, Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G/A — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | 8-K — Instil Bio, Inc. | View Filing | |
| edgar index | EFFECT — Instil Bio, Inc. | View Filing | |
| edgar index | UPLOAD — Instil Bio, Inc. | View Filing | |
| edgar index | CORRESP — Instil Bio, Inc. | View Filing | |
| edgar index | SC 13G/A — Instil Bio, Inc. | View Filing |